Illumina (ILMN) Shares are Up 0.28%

Illumina (ILMN) : Traders are bullish on Illumina (ILMN) as it has outperformed the S&P 500 by a wide margin of 11.15% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.22%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.28% in the last 1 week, and is up 12.29% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 4.43% and the 50-Day Moving Average is 12.25%. Illumina (NASDAQ:ILMN): On Fridays trading session , Opening price of the stock was $167.27 with an intraday high of $167.85. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $166.2. However, the stock managed to close at $166.99, a loss of 0.61% for the day. On the previous day, the stock had closed at $168.02. The total traded volume of the day was 568,766 shares.


The company Insiders own 1.6% of Illumina shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -19.42% . Institutional Investors own 94.04% of Illumina shares. During last six month period, the net percent change held by insiders has seen a change of -23.52%. Also, Brokerage firm Argus Research maintains its rating on Illumina (NASDAQ:ILMN). As per the latest information, the brokerage house raises the price target to $185 per share from a prior target of $175. The shares have been rated Buy. The rating by the firm was issued on August 8, 2016.

Illumina, Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems, consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms, reagent kits and scanning equipment. Its customers include genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories, pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research, including de novo sequencing, genetic variation analysis, epigenetics and targeted screening, among others. It also provides products and services for other life sciences applied markets, such as agrigenomics. It also offers Clarity Run Manager, Clarity LIMS Silver and Clarity LIMS Gold.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.